期刊文献+

CA153在乳腺癌免疫治疗中的作用 被引量:8

The role of CA153 in breast cancer immunotherapy
下载PDF
导出
摘要 乳腺癌是女性常见的恶性肿瘤,免疫治疗是临床上取得较好效果的治疗手段之一。CA153可在乳腺癌免疫应答中作为特异性抗原激活免疫应答;参与T细胞活化;靶向结合多肽疫苗,增强免疫应答;诱导树突状细胞成熟,清除体内癌细胞等。因此CA153在乳腺癌的免疫应答和治疗中具有重要的作用,可作为乳腺癌免疫治疗的新靶点。 Breast cancer is a common malignant tumor in women,and immunotherapy is one of the treatments with a good clinical prognosis.CA153 can activate immune response as a specific antigen in breast cancer immune response;participate in T cell activation;target binding peptide vaccine;enhance immune response;induce dendritic cell maturation,and eliminate cancer cells in vivo.Therefore,CA153 plays an important role in the immune response and treatment of breast cancer,and can be used as a new target for breast cancer immunotherapy.
作者 曹涤非 黄国庆 薛佳莹 吴琼 王雷 李瑶 CAO Difei;HUANG Guoqing;XUE Jiaying;WU Qiong;WANG Lei;LI Yao(Institute of Advanced Technology,Heilongjiang Academy of Sciences,Harbin 150020,China)
出处 《实用肿瘤学杂志》 CAS 2019年第6期566-569,共4页 Practical Oncology Journal
关键词 CA153 乳腺癌 免疫治疗 靶点 CA153 Breast cancer Immunotherapy Target
  • 相关文献

参考文献1

二级参考文献15

  • 1E. A. Eisenhauer, P. Therasse, J. Bogaerts, et al. New re- sponse evaluation criteria in solid tumours: Revised RE- CIST guideline (version 1. 1 ) [J]. European Journal of Cancer,2009,45 ( 2 ) :228 - 247.
  • 2AshworthTR. A case of cancer in which ceils similar to those in the tumours were seen in the blood after death[J]. Aust- Med J,1869,(14) :146 -149.
  • 3Tibbe AG, de Grooth BG, Greve J, et al. Cell analysis system based on immunomagnetic cell selection and alignment fol- lowed by immunofluorescent analysis using compact disk technologies[J]. Cytometry ,2001, (43) :31 - 37.
  • 4Allard WJ, Matera J, Miller MC, et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases[J]. Clin Cancer Res,2004, (10) :6897 -6904.
  • 5Massimo Cristofanilli, M. D, G. Thomas Budd, et al. Circu- lating Tumor Cells, Disease Progression, and Survival in Me- tastatic Breast Cancer [J]. N Engl J Med,2004,351:781 - 791.
  • 6Jean - Yves Pierga, Franqois - Clement Bidard, Claire Ma- thiot, et al. Randomized Trial and Locally Advanced Breast Cancer in a Phase Ⅱ Relapse After Neoadjuvant Chemo- therapy in Large Operable Circulating Tumor Cell Detection Predicts Early Metastatic [J]. Clin Cancer Res, 2008, (14) :7004 -7010.
  • 7A. Giordanol, M. Giuliano, M. De Laurentiis, et al. Circulat- ing tumor cells in immunohistochemical subtypes of meta- static breast cancer: lack of prediction in HER2 - positive disease treated with targeted therapy [J]. Anna1 of oncology,.2012,23(5):1144 -1150.
  • 8Dorit Laessig, Dorothea Nagel, Volker Helnemann, et al. Im- portance of CEA and CA 15 - 3 during Disease Progres- sionin Metastatic Breast Cancer Patients[J]. ANTICANCER RESEARCH ,2007,27 (4A) : 1963 - 1968.
  • 9Duffy MJ, Evoy D, McDermott EW, et al. CA 15 -3: uses and limitation as a biomarker for breast cancer [J]. Clin Chim Acta,2010,411 (23 -24) :1869 - 1874.
  • 10Yerushalmi R, Tyldesley S, Kennecke HAnn Oncol, et al. Tumor markers in metastatic breast cancer subtypes: fre- quency of elevation and correlation with outcome [J]. Ann 0ncol,2012,23(2) : 338 -345.

共引文献5

同被引文献81

引证文献8

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部